Merrill Lynch Upgrades Savient Pharmaceuticals (SVNT) to Buy
Merrill Lynch upgrades Savient Pharmaceuticals (NASDAQ: SVNT) from Neutral to Buy.
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company engaged in developing and distributing pharmaceutical products that target unmet medical needs in markets.
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company engaged in developing and distributing pharmaceutical products that target unmet medical needs in markets.
